ASCO/EHA/ICML 2023 – Paolo Strati
Paolo Strati overviews how patient outcomes can be optimized with current therapies in relapsed or refractory diffuse large B-cell lymphoma in later lines and outlines which innovative approaches might become available in the long run for the treatment of R/R DLBCL. Finally, he explains what can be achieved today in patients with follicular lymphoma and high tumor burden and depicts his personal highlights from this year’s EHA congress.
Here is the full ASCO/EHA/ICML 2023 report.
More posts
Preface – ASCO/EHA/ICML 2023
Cutting-edge updates in the diagnosis and treatment of hematological malignancies were discussed by world-leading experts at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, 2nd–6th June 2023, the European Hematology Association (EHA) congress in Frankfurt, Germany, 8th–11th June 2023, and the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, 13th–17th June 2023.
